Pulmonx (LUNG) Receivables (2019 - 2025)

Pulmonx (LUNG) has 7 years of Receivables data on file, last reported at $12.1 million in Q4 2025.

• Receivables for Q4 2025 came in at $12.1 million, down 7.99% year-over-year; the trailing twelve-month figure through Dec 2025 was $12.1 million (down 7.99% YoY), and the FY2025 annual result was $12.1 million, down 7.99% from the prior year.
• Receivables retreated to $12.1 million in Q4 2025 per LUNG's latest filing, from $13.8 million in the prior quarter.
• Over five years, Receivables peaked at $15.9 million in Q2 2025 and troughed at $5.1 million in Q1 2021.
• A 5-year average of $9.9 million and a median of $9.5 million in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2021 and 2025: Receivables soared 55.2% in 2021, then slipped 7.99% in 2025.
• A 5-year view of Receivables shows it stood at $6.6 million in 2021, then surged by 32.23% to $8.7 million in 2022, then soared by 39.51% to $12.1 million in 2023, then increased by 8.38% to $13.1 million in 2024, then retreated by 7.99% to $12.1 million in 2025.
• Business Quant data shows LUNG's Receivables at $12.1 million in Q4 2025, $13.8 million in Q3 2025, and $15.9 million in Q2 2025.